Osteochondral LesionNCT07555899
Evaluation of the Osteointegrative and Regenerative Capacity of a Scaffold Enriched With Bone Marrow-Derived Cells at the Subchondral Level, Associated With Retrograde Drilling
A study testing Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling. in people with Osteochondral Lesion, run by Istituto Ortopedico Rizzoli at 1 site in Italy.
Trial summary
Osteochondral lesions of the ankle (OsteoChondral Lesions - OCLs) are defects of the subchondral bone and the overlying articular cartilage that commonly affect young and active patients. The main symptoms include chronic ankle pain, recurrent swelling, stiffness, and instability. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Osteochondral Lesion
- What is being tested?
- Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteItaly
- Study dates
- 30 Jan 2026to Feb 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients with one or more chronic cystic subchondral lesions of the talus (Grade IIA according to the Giannini classification); Patients with one or more chronic subchondral lesions with intact cartilage or large chronic OCLs (Grade IIA according to the Giannini classification); Age ≥ 18 years and ≤ 55 years; Ankle pain with limitation in normal activities of daily living (American Orthopaedic Foot and Ankle Score - AOFAS < 85, Short Form-36 - SF-36 < 86); Patients able to provide written informed consent to participate in the study.
Who cannot join
- Patients < 18 years or > 55 years of age; Presence of active infections at the time of study inclusion; Positive status for HIV, HBV, or HCV; Pregnancy; Patients with autoimmune or rheumatologic diseases; Disorders of the immune system; Presence of severe malalignment of the tibiotalar joint in the coronal plane, whether supra-, intra-, or infra-articular (distal tibial articular angle < or > 10°, talar tilt > 8°, severe cavus or flatfoot); Any other condition or disease that contraindicates surgical treatment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Istituto Ortopedico Rizzoli
Bologna
Cesare Faldini, MD, 0516445064, cesare.faldini@ior.it
About this study
Osteochondral lesions of the ankle (OsteoChondral Lesions - OCLs) are defects of the subchondral bone and the overlying articular cartilage that commonly affect young and active patients. The main symptoms include chronic ankle pain, recurrent swelling, stiffness, and instability. The ideal treatment for OCLs remains a matter of debate. Various surgical techniques have been proposed, both arthroscopic and open. The choice of treatment depends on several factors, including lesion pathology, patient characteristics, and surgeon preference.
In the presence of subchondral cysts or lesions with intact and stable cartilage surfaces, retrograde drilling is among the most commonly used techniques. This is a reparative, extra-articular procedure that reaches the lesion via a retrograde approach, thereby preventing iatrogenic cartilage damage. The surgical technique involves creating multiple channels in the subchondral bone using a Kirschner wire to stimulate the migration of mesenchymal stem cells, promote revascularization of the lesion site, and induce new bone formation.
Read more
Although retrograde drilling has shown good results over the years, concerns remain regarding the regenerative potential of subchondral bone, particularly in the case of large lesions or cysts. For this reason, various biological adjuncts have been combined with drilling in an attempt to improve treatment efficacy, with inconclusive results. Among the proposed modifications is that of Beck et al., who expanded the talar tunnel to allow for improved debridement, subsequently filling it with bone graft.
Another treatment option is subchondroplasty, which has shown promising results; however, few studies are available for the ankle, and significant complications have been reported. Therefore, the management of large subchondral cysts remains controversial.
In cases of large OCLs with cartilage damage, regenerative treatments are generally preferred, and several surgical techniques can be performed. However, these approaches are also controversial, as they are typically performed via an anterograde approach and involve extensive debridement of the overlying damaged cartilage, sometimes removing healthy cartilage as well. Significant improvements in AOFAS scores have been reported for all currently used techniques, but none has emerged as the gold standard. Consequently, clinical research is focused on developing new interventions that demonstrate superiority over traditional techniques.
In this context, subendocondral regenerative treatment has gained interest. This approach involves the application of a bone marrow-derived scaffold combined with retrograde drilling in patients with subchondral cysts and intact cartilage or large OCLs of the ankle. This innovative surgical technique combines several procedures already validated in the literature, aiming to leverage their advantages and enhance overall efficacy.
First, it includes an intra-articular arthroscopic approach to assess cartilage status, remove loose bodies, and treat associated conditions such as synovitis, soft tissue impingement, exostoses, and osteophytes. After confirming the appropriate indication based on arthroscopic findings, a Kirschner wire is inserted retrogradely into the lesion under fluoroscopic guidance. Retrograde drilling is then performed using a dedicated reamer.
The novelty of this procedure lies in the placement of a hyaluronic scaffold enriched with bone marrow-derived cells beneath the cartilage, which is therefore not further disrupted. This fully biodegradable scaffold creates a favorable microenvironment for regeneration by supporting the adhesion of bone marrow-derived stem cells and their three-dimensional organization, thereby facilitating restoration of normal tissue anatomy. Large subchondral cysts have shown limited healing potential due to poor vitality of the subchondral bone and a lack of mesenchymal stem cells needed for lesion repair. Therefore, a cartilage scaffold enriched with bone marrow-derived cells may represent an important source of mesenchymal stem cells and promote cellular interaction and mechanical stability during the regenerative process.
This scaffold has been approved for the repair of chondral or osteochondral lesions; however, clinical and MRI outcomes following its subchondral placement in the presence of intact cartilage have not yet been described.
The aim of this pilot study is to evaluate the clinical and imaging outcomes of this innovative surgical technique for subchondral regenerative treatment, which involves the application of a scaffold enriched with bone marrow-derived cells combined with retrograde drilling in patients with subchondral cysts and intact cartilage or large osteochondral lesions of the talus.
- Conditions
- Osteochondral Lesion
- Being tested
- Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling.Other
First, the procedure includes an intra-articular arthroscopic approach to assess the condition of the cartilage, remove any loose bodies, and treat associated conditions such as synovitis, soft tissue impingement, exostoses, and osteophytes. After confirming the appropriate indication based on arthroscopic findings, a Kirschner wire is inserted retrogradely into the lesion under fluoroscopic guidance. Retrograde drilling is then performed using a dedicated reamer.
The novelty of this procedure lies in the placement of a hyaluronic scaffold enriched with bone marrow-derived cells beneath the cartilage, which is therefore not further disrupted. This fully biodegradable scaffold creates a favorable microenvironment for regeneration by supporting the adhesion of bone marrow stem cells and their three-dimensional organization, thereby facilitating restoration of normal tissue anatomy. Large subchondral cysts have shown limited healing potential due to poor vitality of the subchondral bone a
| Study group | Role | What they receive |
|---|---|---|
| Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchon | Experimental | Not described Receives: Other: Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate clinical and imaging outcomes in patients treated with retrograde drilling and application of bone marrow aspirate on a scaffold for the treatment of subchondral cysts with intact cartilage or large osteochondral lesions of the ankle at the d
Measured: january 2026 - january 2028
Secondary outcomes (1)
To evaluate MRI outcomes at 12 months using the T2 mapping protocol, which allows assessment of the biomechanical properties of the cartilage matrix, including collagen content and water percentage, by subjecting patients to MRI. The images will be indep
Measured: january 2026 - january 2028
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start30 Jan 2026
- Primary completionJan 2028 (estimated)
- Study completionFeb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Osteochondral LesionStudies of the same condition, open and under way.
- More trials run by Istituto Ortopedico RizzoliThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istituto Ortopedico Rizzoli
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cesare Faldini, Istituto Ortopedico Rizzoli
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07555899
- Sponsor's protocol ID
- CASPARD
- Status last verified
- Apr 2026
- First submitted
- 21 Apr 2026
- Last updated
- 29 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Osteointegrative and Regenerative Capacity of a Scaffold Enriched With Bone Marrow-Derived Cells at the Subchondral Level, Associated With Retrograde Drilling
- ClinicalTrials.gov ID
- NCT07555899
- Acronym / sponsor ID
- CASPARD
- Conditions
- Osteochondral Lesion
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Istituto Ortopedico RizzoliUniversity, hospital or other
- Study start
- 30 Jan 2026 (actual)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Feb 2028 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Osteochondral lesions of the ankle (OsteoChondral Lesions - OCLs) are defects of the subchondral bone and the overlying articular cartilage that commonly affect young and active patients. The main symptoms include chronic ankle pain, recurrent swelling, stiffness, and instability. The ideal treatment for OCLs remains a matter of debate. Various surgical techniques have been proposed, both arthroscopic and open. The choice of treatment depends on several factors, including lesion pathology, patient characteristics, and surgeon preference.
In the presence of subchondral cysts or lesions with intact and stable cartilage surfaces, retrograde drilling is among the most commonly used techniques. This is a reparative, extra-articular procedure that reaches the lesion via a retrograde approach, thereby preventing iatrogenic cartilage damage. The surgical technique involves creating multiple channels in the subchondral bone using a Kirschner wire to stimulate the migration of mesenchymal stem cells, promote revascularization of the lesion site, and induce new bone formation.
Although retrograde drilling has shown good results over the years, concerns remain regarding the regenerative potential of subchondral bone, particularly in the case of large lesions or cysts. For this reason, various biological adjuncts have been combined with drilling in an attempt to improve treatment efficacy, with inconclusive results. Among the proposed modifications is that of Beck et al., who expanded the talar tunnel to allow for improved debridement, subsequently filling it with bone graft.
Another treatment option is subchondroplasty, which has shown promising results; however, few studies are available for the ankle, and significant complications have been reported. Therefore, the management of large subchondral cysts remains controversial.
In cases of large OCLs with cartilage damage, regenerative treatments are generally preferred, and several surgical techniques can be performed. However, these approaches are also controversial, as they are typically performed via an anterograde approach and involve extensive debridement of the overlying damaged cartilage, sometimes removing healthy cartilage as well. Significant improvements in AOFAS scores have been reported for all currently used techniques, but none has emerged as the gold standard. Consequently, clinical research is focused on developing new interventions that demonstrate superiority over traditional techniques.
In this context, subendocondral regenerative treatment has gained interest. This approach involves the application of a bone marrow-derived scaffold combined with retrograde drilling in patients with subchondral cysts and intact cartilage or large OCLs of the ankle. This innovative surgical technique combines several procedures already validated in the literature, aiming to leverage their advantages and enhance overall efficacy.
First, it includes an intra-articular arthroscopic approach to assess cartilage status, remove loose bodies, and treat associated conditions such as synovitis, soft tissue impingement, exostoses, and osteophytes. After confirming the appropriate indication based on arthroscopic findings, a Kirschner wire is inserted retrogradely into the lesion under fluoroscopic guidance. Retrograde drilling is then performed using a dedicated reamer.
The novelty of this procedure lies in the placement of a hyaluronic scaffold enriched with bone marrow-derived cells beneath the cartilage, which is therefore not further disrupted. This fully biodegradable scaffold creates a favorable microenvironment for regeneration by supporting the adhesion of bone marrow-derived stem cells and their three-dimensional organization, thereby facilitating restoration of normal tissue anatomy. Large subchondral cysts have shown limited healing potential due to poor vitality of the subchondral bone and a lack of mesenchymal stem cells needed for lesion repair. Therefore, a cartilage scaffold enriched with bone marrow-derived cells may represent an important source of mesenchymal stem cells and promote cellular interaction and mechanical stability during the regenerative process.
This scaffold has been approved for the repair of chondral or osteochondral lesions; however, clinical and MRI outcomes following its subchondral placement in the presence of intact cartilage have not yet been described.
The aim of this pilot study is to evaluate the clinical and imaging outcomes of this innovative surgical technique for subchondral regenerative treatment, which involves the application of a scaffold enriched with bone marrow-derived cells combined with retrograde drilling in patients with subchondral cysts and intact cartilage or large osteochondral lesions of the talus.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchon | Experimental | Other: Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Patients with one or more chronic cystic subchondral lesions of the talus (Grade IIA according to the Giannini classification); Patients with one or more chronic subchondral lesions with intact cartilage or large chronic OCLs (Grade IIA according to the Giannini classification); Age ≥ 18 years and ≤ 55 years; Ankle pain with limitation in normal activities of daily living (American Orthopaedic Foot and Ankle Score - AOFAS < 85, Short Form-36 - SF-36 < 86); Patients able to provide written informed consent to participate in the study.
Key exclusion criteria (1 listed)
- Patients < 18 years or > 55 years of age; Presence of active infections at the time of study inclusion; Positive status for HIV, HBV, or HCV; Pregnancy; Patients with autoimmune or rheumatologic diseases; Disorders of the immune system; Presence of severe malalignment of the tibiotalar joint in the coronal plane, whether supra-, intra-, or infra-articular (distal tibial articular angle < or > 10°, talar tilt > 8°, severe cavus or flatfoot); Any other condition or disease that contraindicates surgical treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling.First, the procedure includes an intra-articular arthroscopic approach to assess the condition of the cartilage, remove any loose bodies, and treat associated conditions such as synovitis, soft tissue impingement, exostoses, and osteophytes. After confirming the appropriate indication based on arthroscopic findings, a Kirschner wire is inserted retrogradely into the lesion under fluoroscopic guidance. Retrograde drilling is then performed using a dedicated reamer. The novelty of this procedure lies in the placement of a hyaluronic scaffold enriched with bone marrow-derived cells beneath the cartilage, which is therefore not further disrupted. This fully biodegradable scaffold creates a favorable microenvironment for regeneration by supporting the adhesion of bone marrow stem cells and their three-dimensional organization, thereby facilitating restoration of normal tissue anatomy. Large subchondral cysts have shown limited healing potential due to poor vitality of the subchondral bone a | Other | Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchon |
Primary outcome
To evaluate clinical and imaging outcomes in patients treated with retrograde drilling and application of bone marrow aspirate on a scaffold for the treatment of subchondral cysts with intact cartilage or large osteochondral lesions of the ankle at the d
Time frame: january 2026 - january 2028
1 secondary outcome
To evaluate MRI outcomes at 12 months using the T2 mapping protocol, which allows assessment of the biomechanical properties of the cartilage matrix, including collagen content and water percentage, by subjecting patients to MRI. The images will be indep
Time frame: january 2026 - january 2028
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
Related trials for Osteochondral Lesion
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
Knee Pain Chronic, Knee Osteoarthritis
RecruitingPhase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Chondral Defect, Articular Cartilage Defect
Active, not recruiting
Episealer® Knee System IDE Clinical Study
Degenerative Lesion of Articular Cartilage of Knee
Recruiting
MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
Osteochondral Lesions of the Knee Joint, Osteochondritis Dissecans (OCD)
Active, not recruiting
Early Feasibility Study of Cartilage Defect Repair
Osteoarthritis, Hip, Femoroacetabular Impingement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling. in people with Osteochondral Lesion, run by Istituto Ortopedico Rizzoli at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Antotnio Mazzotti, MD PhD (+39 349 879 8863, antonio.mazzotti@ior.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate clinical and imaging outcomes in patients treated with retrograde drilling and application of bone marrow aspirate on a scaffold for the treatment of subchondral cysts with intact cartilage or large osteochondral lesions of the ankle at the d (time frame: january 2026 - january 2028). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.